Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: A detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry.

Autor: Manatunga DC; Department of Chemistry, University of Colombo, Colombo 00300, Sri Lanka., de Silva RM; Department of Chemistry, University of Colombo, Colombo 00300, Sri Lanka. Electronic address: rohini@chem.cmb.ac.lk., de Silva KMN; Department of Chemistry, University of Colombo, Colombo 00300, Sri Lanka; Sri Lanka Institute of Nanotechnology (SLINTEC), Nanotechnology & Science Park, Mahenwatte, Pitipana, Homagama 10206, Sri Lanka., Malavige GN; Center for Dengue Research, Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, 10250, Sri Lanka., Wijeratne DT; Center for Dengue Research, Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, 10250, Sri Lanka., Williams GR; UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom., Jayasinghe CD; Department of Zoology, University of Colombo, Colombo 00300, Sri Lanka., Udagama PV; Department of Zoology, University of Colombo, Colombo 00300, Sri Lanka.
Jazyk: angličtina
Zdroj: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2018 Jul; Vol. 128, pp. 18-26. Date of Electronic Publication: 2018 Apr 03.
DOI: 10.1016/j.ejpb.2018.04.001
Abstrakt: This study was focused on developing a drug carrier system composed of a polymer containing hydroxyapatite (HAp) shell and a magnetic core of iron oxide nanoparticles. Doxorubicin and/or curcumin were loaded into the carrier via a simple diffusion deposition approach, with encapsulation efficiencies (EE) for curcumin and doxorubicin of 93.03 ± 0.3% and 97.37 ± 0.12% respectively. The co-loading of curcumin and doxorubicin led to a total EE of 76.02 ± 0.48%. Release studies were carried out at pH 7.4 and 5.3, and revealed a greater extent of release at pH 5.3, showing the formulations to have potential applications in tumor microenvironments. Cytotoxicity assays, fluorescence imaging and flow cytometry demonstrated that the formulations could effectively inhibit the growth of MCF-7 (breast) and HEpG2 (liver) cancer cells, being more potent than the free drug molecules both in terms of dose and duration of action. Additionally, hemolysis tests and cytotoxicity evaluations determined the drug-loaded carriers to be non-toxic towards non-cancerous cells. These formulations thus have great potential in the development of new cancer therapeutics.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: